These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32875998)

  • 1. Controversies with testosterone therapy.
    Khera M
    Can J Urol; 2020 Aug; 27(S3):20-23. PubMed ID: 32875998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controversies in Testosterone Therapy.
    Twitchell DK; Pastuszak AW; Khera M
    Sex Med Rev; 2021 Jan; 9(1):149-159. PubMed ID: 33309270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk.
    Khera M; Miner M; Jaffe J; Pastuszak AW
    J Sex Med; 2021 Jan; 18(1):83-98. PubMed ID: 33317996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone.
    Fallara G; Pozzi E; Belladelli F; Corsini C; Boeri L; Capogrosso P; Montorsi F; Salonia A
    J Sex Med; 2022 Aug; 19(8):1243-1254. PubMed ID: 35753891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Testosterone Therapy in the Setting of Prostate Cancer.
    Rodriguez KM; Pastuszak AW; Khera M
    Curr Urol Rep; 2018 Jun; 19(8):67. PubMed ID: 29961247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature.
    Natale C; Carlos C; Hong J; Khera M; Baum N; Raheem OA
    Sex Med Rev; 2021 Jul; 9(3):393-405. PubMed ID: 33516741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size.
    Yassin A; Alwani M; Al-Zoubi RM; Aboumarzouk OM; Talib R; Nettleship J; Kelly D; Albaba B
    Int Urol Nephrol; 2023 Jul; 55(7):1649-1658. PubMed ID: 37148486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies.
    Corona G; Rastrelli G; Di Pasquale G; Sforza A; Mannucci E; Maggi M
    J Sex Med; 2018 Jun; 15(6):820-838. PubMed ID: 29803351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is testosterone a friend or a foe of the prostate?
    Jannini EA; Gravina GL; Morgentaler A; Morales A; Incrocci L; Hellstrom WJ
    J Sex Med; 2011 Apr; 8(4):946-55. PubMed ID: 21457469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone therapy in prostate cancer: is it still a controversy?
    Bart AS; Van Hoof A; Badre-Hume R; Selvarajah J; Robillard K; Albala DM
    Curr Opin Urol; 2022 Nov; 32(6):598-606. PubMed ID: 36081393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone treatment and change of categories of the International prostate symptom score (IPSS) in hypogonadal patients: 12 years prospective controlled registry study.
    Yassin A; Kelly D; Nettleship J; Talib R; Al-Zoubi RM; Aboumarzouk OM; Albaba B
    Aging Male; 2023 Dec; 26(1):2220567. PubMed ID: 37287273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
    Saad F; Caliber M; Doros G; Haider KS; Haider A
    Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms.
    Saad F; Doros G; Haider KS; Haider A
    Investig Clin Urol; 2018 Nov; 59(6):399-409. PubMed ID: 30402573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular impact of testosterone therapy for hypogonadism.
    Rastrelli G; Dicuio M; Reismann Y; Sforza A; Maggi M; Corona G
    Expert Rev Cardiovasc Ther; 2018 Sep; 16(9):617-625. PubMed ID: 30099911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypogonadism: Therapeutic Risks, Benefits, and Outcomes.
    Sigalos JT; Pastuszak AW; Khera M
    Med Clin North Am; 2018 Mar; 102(2):361-372. PubMed ID: 29406064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial.
    Rastrelli G; Cipriani S; Lotti F; Cellai I; Comeglio P; Filippi S; Boddi V; Della Camera PA; Santi R; Boni L; Nesi G; Serni S; Gacci M; Maggi M; Vignozzi L
    J Endocrinol Invest; 2022 Jul; 45(7):1413-1425. PubMed ID: 35298833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternatives to Testosterone Therapy: A Review.
    Lo EM; Rodriguez KM; Pastuszak AW; Khera M
    Sex Med Rev; 2018 Jan; 6(1):106-113. PubMed ID: 29174957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine.
    Morgentaler A; Traish A; Hackett G; Jones TH; Ramasamy R
    Sex Med Rev; 2019 Oct; 7(4):636-649. PubMed ID: 31351915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.
    Chen T; Li S; Eisenberg ML
    J Sex Med; 2021 Aug; 18(8):1346-1353. PubMed ID: 34303630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.
    Corona G; Rastrelli G; Morgentaler A; Sforza A; Mannucci E; Maggi M
    Eur Urol; 2017 Dec; 72(6):1000-1011. PubMed ID: 28434676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.